We have located links that may give you full text access.
ENGLISH ABSTRACT
JOURNAL ARTICLE
[Mitral valve repair for the treatment of ischemic mitral regurgitation].
Twenty-six patients with moderate and severe ischemic mitral regurgitation due to papillary muscle dysfunction underwent mitral valve replacement (MVR) or mitral annuloplasty (MAP) using modified Kay method. Emergent operation was performed in 12 patients of whom 11 had severe congestive heart failure even under IABP, 5 had cardiogenic shock and 9 needed respiratory care with intubation preoperatively. Elective operation was performed in 14 patients of whom 6 had history of congestive heart failure and 1 had episodes of ventricular tachycardia. As intraoperative findings of mitral valve, mural annular dilatation in 84.6%, prolapse of anterior leaflet in 23.1%, papillary muscle scar in 15.4%, chordal elongation in 15.4% and chordal rupture in 3.8% were seen separately or in combination. In 22 patients MAP using modified Kay method and CABG were performed, but in 4 patients MVR was needed because of the prominent prolapse of the anterior leaflet. Fourteen patients who underwent MAP with CABG and one MVR with CABG survived. Hospital mortality was higher in emergent (58.5%) than elective operation (28.6%). In the 15 survivors, mitral regurgitation decreased below Sellers 2, pulmonary wedge pressure decreased significantly (p < 0.01) and NYHA functional class improved to I or II postoperatively. During the follow up period of 15-100 (mean 38.7 +/- 21.6) months, 2 MAP+CABG patients died suddenly, but the remaining 13 patients were in NYHA class I or II and no progression of MR was seen. These results indicated that MAP+CABG is recommendable in the treatment of ischemic mitral regurgitation due to papillary muscle dysfunction, in order to preserve cardiac function and to reduce valve related complications.
Full text links
Trending Papers
A Personalized Approach to the Management of Congestion in Acute Heart Failure.Heart International 2023
Potential Mechanisms of the Protective Effects of the Cardiometabolic Drugs Type-2 Sodium-Glucose Transporter Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Heart Failure.International Journal of Molecular Sciences 2024 Februrary 21
The Effect of Albumin Administration in Critically Ill Patients: A Retrospective Single-Center Analysis.Critical Care Medicine 2024 Februrary 8
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app